Literature DB >> 19079052

Antigenic variation in Giardia lamblia is regulated by RNA interference.

César G Prucca1, Ileana Slavin, Rodrigo Quiroga, Eliana V Elías, Fernando D Rivero, Alicia Saura, Pedro G Carranza, Hugo D Luján.   

Abstract

Giardia lamblia (also called Giardia intestinalis) is one of the most common intestinal parasites of humans. To evade the host's immune response, Giardia undergoes antigenic variation-a process that allows the parasite to develop chronic and recurrent infections. From a repertoire of approximately 190 variant-specific surface protein (VSP)-coding genes, Giardia expresses only one VSP on the surface of each parasite at a particular time, but spontaneously switches to a different VSP by unknown mechanisms. Here we show that regulation of VSP expression involves a system comprising RNA-dependent RNA polymerase, Dicer and Argonaute, known components of the RNA interference machinery. Clones expressing a single surface antigen efficiently transcribe several VSP genes but only accumulate transcripts encoding the VSP to be expressed. Detection of antisense RNAs corresponding to the silenced VSP genes and small RNAs from the silenced but not for the expressed vsp implicate the RNA interference pathway in antigenic variation. Remarkably, silencing of Dicer and RNA-dependent RNA polymerase leads to a change from single to multiple VSP expression in individual parasites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19079052     DOI: 10.1038/nature07585

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  86 in total

1.  Characterization of the unusual bidirectional ves promoters driving VESA1 expression and associated with antigenic variation in Babesia bovis.

Authors:  Xinyi Wang; Yu-Ping Xiao; Anne Bouchut; Basima Al-Khedery; Hongbin Wang; David R Allred
Journal:  Eukaryot Cell       Date:  2012-01-27

2.  Calling all antigens.

Authors:  Kirk Deitsch
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

Review 3.  MicroRNAs of parasites: current status and future perspectives.

Authors:  Quan Liu; Wenbin Tuo; Hongwei Gao; Xing-Quan Zhu
Journal:  Parasitol Res       Date:  2010-06-08       Impact factor: 2.289

4.  Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia.

Authors:  Barbara J Davids; Ching M Liu; Elaine M Hanson; Christine H Y Le; Jonathan Ang; Kurt Hanevik; Marvin Fischer; Matej Radunovic; Nina Langeland; Marcela Ferella; Staffan G Svärd; Majid Ghassemian; Yukiko Miyamoto; Lars Eckmann
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

5.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

Review 6.  Giardiasis: a review on assemblage distribution and epidemiology in India.

Authors:  Shakti Laishram; Gagandeep Kang; Sitara Swarna Rao Ajjampur
Journal:  Indian J Gastroenterol       Date:  2012-02-07

Review 7.  The emerging world of small silencing RNAs in protozoan parasites.

Authors:  Vanessa D Atayde; Christian Tschudi; Elisabetta Ullu
Journal:  Trends Parasitol       Date:  2011-04-15

8.  Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens.

Authors:  Jeffrey W Priest; Delynn M Moss; Govinda S Visvesvara; Cara C Jones; Anna Li; Judith L Isaac-Renton
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

9.  Using morpholinos for gene knockdown in Giardia intestinalis.

Authors:  Meredith L Carpenter; W Zacheus Cande
Journal:  Eukaryot Cell       Date:  2009-04-17

10.  Cytokines, Antibodies, and Histopathological Profiles during Giardia Infection and Variant-Specific Surface Protein-Based Vaccination.

Authors:  Marianela C Serradell; Pablo R Gargantini; Alicia Saura; Sergio R Oms; Lucía L Rupil; Luciana Berod; Tim Sparwasser; Hugo D Luján
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.